{ "docId": "019dd923-622c-750b-8b99-bca3fd68622d", "docSlug": "4c8fe6013c68", "documentTitle": "iRhythm Technologies, Inc. (IRTC)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-18 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 13, "pageCount": 101, "prevPage": 12, "nextPage": 14, "slideType": "thesis_headline", "function": "frame_problem", "density": "overcrowded", "nDataPoints": 6, "notes": "Includes a direct quote from a regulatory consultant to emphasize the severity of the risk.", "elementsJson": [ "headline_text", "paragraph", "callout_box", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/13", "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-13", "components": [ { "bbox": { "h": 0.05, "w": 0.96, "x": 0.02, "y": 0.55 }, "kind": "callout", "text": "Regulatory Experts See Real Odds of a Negative Outcome", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7e79425a-458d-4ed6-9078-0489506cd3c3", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "callout", "text": "We view iRhythm as a low-margin supplier of a largely commoditized product, yet the Company is currently trading at an approximate 100% premium to other medical device companies.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-0395-748f-9564-e4ef4c3b6984", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "metric", "text": "downside risk: 40% to 70%", "attrs": null, "subkind": "primary", "toolName": "Quantification", "toolSlug": "quantification", "confidence": null, "componentId": "019dd953-0395-748f-9564-ee758022928a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.96, "x": 0.02, "y": 0.17 }, "kind": "paragraph", "text": "We Believe Investors Are Using the Wrong Comparable Companies For Valuation", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "994938bd-27e8-4707-9e14-673f610d221d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.31, "w": 0.96, "x": 0.02, "y": 0.22 }, "kind": "paragraph", "text": "Despite allegedly endangering patients and the specter of legal liability, iRhythm shares have rallied to near a two-year high. Even Wall Street analysts, who we believe are largely ignoring both the regulatory risks and looming growth headwinds, are having a hard time justifying iRhythm’s inflated stock price. Despite all but one of the 13 analysts having a “Buy” rating on iRhythm shares, the average price target represents just 11% upside from current. We view iRhythm as a low-margin supplier of a largely commoditized product, yet the Company is currently trading at an approximate 100% premium to other medical device companies. Arguably, iRhythm is actually a services company, a position clearly endorsed by one of the Company’s former CFOs. This is problematic for the stock, since the Company is trading at an approximate 200% premium to medical testing services companies, which we believe more closely approximate iRhythm’s CCT operations and thus represent credible comparable companies. Based on our analysis, even assuming iRhythm can meet the Wall Street forecasted revenue range in 2026, we derive a price target range of $43 to $94 per share, representing approximately 40% to 70% downside from current and material risk of underperformance relative to medical device and services industry peers and the broader market.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ec71e575-1c06-4bbc-8f98-e899eccc2014", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.73, "x": 0.25, "y": 0.61 }, "kind": "quote", "text": "[if] people are being diagnosed incorrectly, and if that led to a death or if that led to somebody getting treated incorrectly, this is a very serious 483. They could actually get a consent decree, and FDA could walk in and shut them down...it is apparent that it’s systemic... ...to be honest, this would really scare me because they’re on the radar of the DOJ. They’ve kind of upset them...They’ve got a mess on their hands...I would truly run away. I wouldn’t touch that company with a 10-foot pole.", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f6b803ad-910e-4f2f-8024-4e73e710e51f", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "\"[if] people are being diagnosed incorrectly, and if that led to a death or if that led to somebody getting treated incorrectly, this is a very serious 483. They could actually get a consent decree, and FDA could walk in and shut them down...it is apparent that it’s systemic...\" \"...to be honest, this would really scare me because they're on the radar of the DOJ. They've kind of upset them...They've got a mess on their hands...I would truly run away. I wouldn't touch that company with a 10-foot pole.\" — Spruce Point Interview with Medical Device Regulatory Compliance Consultant, June 2025", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-0395-748f-9564-ead7f05e70a1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.02, "y": 0.97 }, "kind": "source-note", "text": "Source: Spruce Point research", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "1af22b78-ad9d-4937-97ea-865ddf65f61a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.31, "y": 0.04 }, "kind": "title", "text": "We See 40% To 70% Downside Risk Potential In iRhythm Shares", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c4a66b30-fe32-49b2-b361-6eaaabe122fc", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "from": 8, "beatId": "98bf75b1-d631-41a2-8007-79b7391e3925", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Expose Contradiction", "beatSlug": null, "evidence": "The document presents various contradictions and concerns regarding iRhythm's products and practices.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "loops": [ { "to": 20, "from": 9, "name": "The Reveal", "slug": "05-the-reveal", "bestFor": "Product launches, strategic pivots, unexpected findings", "matchId": "8bdc237c-9f95-46ed-95d1-4a4201a5a71e", "evidence": "The document presents various concerns and criticisms of iRhythm.", "position": 0, "objective": "To reveal concerns about iRhythm's products and management practices", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "confidence": 0.7, "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }